Persistent neurological and neuropsychiatric symptoms affect a substantial fraction of
people after COVID-19 and represent a major component of the post-acute COVID-19 …

Studies in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease
and Amyotrophic lateral sclerosis, Huntington's disease, and so on, have suggested that …

Despite advances in uncovering the mechanisms that underlie neuroinflammation and
neurodegenerative disease, therapies that prevent neuronal loss remain elusive. Targeting …

Background Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease …

Astrocytes are abundant glial cells in the central nervous system (CNS) that perform diverse
functions in health and disease. Astrocyte dysfunction is found in numerous diseases …

In the contexts of aging, injury, or neuroinflammation, activated microglia signaling with TNF-
α, IL-1α, and C1q induces a neurotoxic astrocytic phenotype, classified as A1, A1-like, or …

Microglia activation is observed in various neurodegenerative diseases. Recent advances in
single-cell technologies have revealed that these reactive microglia were with high spatial …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Neuroinflammation is associated with neurodegenerative diseases, such as Alzheimer's
disease, Parkinson's disease, and amyotrophic lateral sclerosis. Microglia and astrocytes …

Astroglia are a broad class of neural parenchymal cells primarily dedicated to homoeostasis
and defence of the central nervous system (CNS). Astroglia contribute to the …